Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2023-01-05 00:00:00 ET · period of report 2023-01-03 · accession 0001104659-23-001495 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-05 | 2023-01-03 | PLX | Schwartz Aharon | Dir | P - Purchase | $1.42 | +110.0K | 174.0K | +172% | +$156.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-03 | P | A | 110,000 | $1.42 | 174,000 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $1.430 to $1.405 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |